# To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors

> **NCT02410174** · PHASE1 · TERMINATED · sponsor: **Beth Israel Medical Center** · enrollment: 3 (actual)

## Conditions studied

- Primary Tumor
- Renal Cell Carcinoma

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT02410174
- **Lead sponsor:** Beth Israel Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor Accural
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410174, "To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02410174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*